Search abstracts

In-situ gelling controlled release injection of rivastigmine to treat Alzheimers disease

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: SAIF, Alasoul (King abdulaziz university, Saudi Arabia)
  • Co-author(s): Rawan othman Almadfaa: pharmacy, king abdulaziz university, jeddah, Saudi Arabia
    Alasoul Saif: pharmacy, king abdulaziz university, jeddah,Saudi Arabia
    Hatoun labban:pharmacy, king abdulaziz university, jeddah,Saudi Arabia
  • Abstract:


    Alzheimer is a neurodegenerative disease that is characterized by deterioration of cognitive & memory functions. Rivastigmine (RIV) is one of the most common drugs available for the treatment. The main challenge for its use is the frequent dosing and compliance to medications. As a result, Alzheimer's patients stop taking rivastigmine


  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 13 May 2019

FIP Congresses